Cambridge Cognition Holdings Plc (LON:COG), which develops and markets digital solutions to assess brain health, has announced that it has won a contract worth just over £1 million with a top 10 pharmaceutical company to provide digital cognitive assessments for a pivotal phase III autoimmune disease trial. Revenue from the contract is expected over the next three years.
Autoimmune diseases occur when a person’s immune system mistakenly attacks healthy cells1 which, for some patients, can result in cognitive impairment. With the prevalence of autoimmune disease on the rise2, there is an urgency to develop better treatments. This need has resulted in a 40% increase in clinical trials for autoimmune conditions in the last decade3. Nevertheless, treatment options for the associated cognitive impairment are limited.
This top 10 pharmaceutical company has selected Cambridge Cognition as the cognitive assessment provider for its pivotal trial as they believe the Company has the technology and infrastructure to deliver rapid, sensitive cognitive assessments at scale. The trial aims to recruit and test hundreds of participants across nearly 40 countries.
Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:
“Phase III clinical trials are the large, final stage in drug development as pharmaceutical companies can use the results to seek regulatory approval. Cambridge Cognition is well positioned to deliver these pivotal, global trials with its gold standard solutions. Strategically, this contract sees the Company operate in a high growth space with a leading pharmaceutical company that is committed to tackling diseases in this therapeutic area.”
References
1. https://www.niehs.nih.gov/health/topics/conditions/autoimmune/index.cfm
2. Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin DC, Chan EKL, Miller FW. Increasing Prevalence of Antinuclear Antibodies in the United States. Arthritis Rheumatol. 2020 Jun;72(6):1026-1035. doi: 10.1002/art.41214. Epub 2020 Apr 30. PMID: 32266792; PMCID: PMC7255943.
